March 3, 2026Open Access

Case Report: Durable disease stability in a patient with MET exon 14 skipping mutation and brain metastasis NSCLC following radiotherapy and immunotherapy

Key Points

Disease stability was observed following radiotherapy and camrelizumab treatment.
Patient had a MET exon 14 skipping mutation and high PD-L1 expression.
Combination therapy showed promise in treating lung adenocarcinoma with brain metastasis.
Findings support further evaluation of immunotherapy in larger lung cancer cohorts.

Abstract

The combination of brain radiotherapy and camrelizumab demonstrated efficacy in a lung adenocarcinoma patient with BM and METex14. These findings suggest that immunotherapy may represent a potential treatment approach for high PD-L1 expression of METex14 NSCLC patients, warranting further investigation in larger cohorts.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Ji Ma

Depeng Zhang

Yang Cui

Journals

Frontiers in Immunology

Actions

Institutions

Shandong University

Shandong First Medical University

Shandong Tumor Hospital

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Case Report: Durable disease stability in a patient with MET exon 14 skipping mutation and brain metastasis NSCLC following radiotherapy and immunotherapy

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study